Early Experience Implementing Long-Acting Injectable Cabotegravir/Rilpivirine for Human Immunodeficiency Virus-1 Treatment at a Ryan White-Funded Clinic in the US South.
Lauren F CollinsDella Corbin-JohnsonMeron AsratZoey P MortonKaylin DanceAlton CondraKimberly JenkinsMarie Todd-TurnerJeri SumitaniBradley L SmithWendy S ArmstrongJonathan A ColasantiPublished in: Open forum infectious diseases (2022)
Implementing LAI-ART at a Southern US Ryan White-funded clinic has been challenged by the following: substantial human resource capital to attain drug, administer injections, and support enrolled patients; delayed therapy initiation due to insurance denials; patient ineligibility primarily due to possible RPV resistance; and inability to provide drug regardless of payor source. These barriers may perpetuate disparities in ART access and outcomes among PWH and should be urgently addressed so that LAI-ART can be offered equitably.
Keyphrases
- human immunodeficiency virus
- antiretroviral therapy
- hiv infected
- end stage renal disease
- hiv infected patients
- hepatitis c virus
- primary care
- ejection fraction
- endothelial cells
- chronic kidney disease
- newly diagnosed
- hiv positive
- hiv aids
- quality improvement
- prognostic factors
- peritoneal dialysis
- stem cells
- emergency department
- affordable care act
- hyaluronic acid
- ultrasound guided
- combination therapy
- health insurance
- induced pluripotent stem cells
- mesenchymal stem cells
- bone marrow